You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR ADAGRASIB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for adagrasib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03785249 ↗ Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 Recruiting Mirati Therapeutics Inc. Phase 1/Phase 2 2019-01-15 This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
NCT04613596 ↗ Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7 Recruiting Mirati Therapeutics Inc. Phase 2 2020-12-02 This Phase 2 study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.
NCT04685135 ↗ Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Recruiting Mirati Therapeutics Inc. Phase 3 2021-01-29 This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
NCT04975256 ↗ Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) Recruiting Boehringer Ingelheim Phase 1 2021-08-12 This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for adagrasib

Condition Name

Condition Name for adagrasib
Intervention Trials
Metastatic Cancer 6
Advanced Cancer 5
Malignant Neoplastic Disease 4
Advanced Solid Tumor 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for adagrasib
Intervention Trials
Neoplasms 9
Lung Neoplasms 9
Carcinoma, Non-Small-Cell Lung 7
Neoplasm Metastasis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for adagrasib

Trials by Country

Trials by Country for adagrasib
Location Trials
United States 104
Italy 8
France 7
Spain 7
Belgium 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for adagrasib
Location Trials
Texas 11
California 7
Colorado 6
New York 6
Virginia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for adagrasib

Clinical Trial Phase

Clinical Trial Phase for adagrasib
Clinical Trial Phase Trials
Phase 3 1
Phase 2 5
Phase 1/Phase 2 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for adagrasib
Clinical Trial Phase Trials
Recruiting 10
Not yet recruiting 9
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for adagrasib

Sponsor Name

Sponsor Name for adagrasib
Sponsor Trials
Mirati Therapeutics Inc. 18
M.D. Anderson Cancer Center 4
Bristol-Myers Squibb 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for adagrasib
Sponsor Trials
Industry 26
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.